Abstract
Currently, high protein and fat food in daily diet often causes the prevalence of gout, which is common treated with colchicine as specific medicine. Transdermal delivery with microemulsion is very attractive for topical colchicine delivery due to its permeation enhancement across the skin barrier. However, the lack of controlled drug release ability compromises the performance of microemulsion for transdermal delivery. Herein, a colchicine transdermal delivery vehicle with one-pot approach that synchronously achieved in situ colchicine encapsulation during nano-hydroxyapatite (Hap) formation inside water/lecithin/n-propanol/isopropyl myristate microemulsion as microreactor was proposed. The optimal formulation was determined at the composition proportion (w/w) of 13% lecithin, 26% n-propanol, 53% IPM, and 8% water. This composite formulation not only possessed high transdermal flux and enhanced drug loading efficiency, but also exhibited a tunable sustained-release behaviour. This composite system combined the transdermal permeation advantage of microemulsion and controlled drug release capacity of nano-Hap, implying a promising vehicle for transdermal delivery of colchicine to produce desirable pharmacological effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
